Technology area: Biotechnology & Pharmaceuticals
23 pending office actions • 9 art units • 21 examiners • 0 of 23 (0%) have an AI response strategy ready • 33 patents granted in the last 365 days
Guardant Health Inc. has 23 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 23 pending office actions are assigned to 21 distinct examiners across 9 distinct art units. This indicates that nearly every pending action is being handled by a different examiner. The 9 distinct art units suggest that the company's biotechnology and pharmaceutical filings fall into several different specialized categories.
The busiest examiner, YU, TIAN NMN, is responsible for 2 busiest examiner pending actions. With 21 distinct examiners involved, the company must manage a wide range of examiner perspectives for its 23 pending office actions. The 2 busiest examiner pending actions represent a small portion of the total workload. Practitioners should coordinate their strategies across the 9 distinct art units to ensure consistency.
The involvement of 21 distinct examiners provides a broad range of feedback on the company's innovations. Practitioners should monitor the 2 busiest examiner pending actions for trends that may impact the other 23 pending office actions. Managing the matters across 9 distinct art units requires a coordinated approach to maintain consistency in the Biotechnology & Pharmaceuticals technology area.
Based on the USPTO statutory response window for each pending office action. 9 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 9 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 4 (17%) |
| §101 + other | 10 (43%) |
| §103 only | 4 (17%) |
| Double-patenting + other | 3 (13%) |
| Multi-statute (no §101) | 2 (9%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WILDER, CYNTHIA B | 2 | 70.8% | +27.0% |
| YU, TIAN NMN | 2 | 55.6% | +19.3% |
| LIU, GUOZHEN | 1 | 48.1% | +26.0% |
| WANG, CHAO | 1 | 80.8% | +81.2% |
| BROWN, MINDY G | 1 | 57.8% | +40.5% |
| KHATTAR, RAJESH | 1 | 36.9% | +35.6% |
| SANGHERA, STEVEN G.S. | 1 | 30.3% | +29.7% |
| GREENE, CAROLYN LEE | 1 | 65.7% | +46.1% |
| MONTGOMERY, ANN Y | 1 | 69.1% | +27.6% |
| JONES, CHRISTINE MICHELLE | 1 | 0.0% | +0.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19221319 | METHODS AND SYSTEMS FOR SECURE SOFTWARE DELIVERY | WANG, CHAO | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16560752 | METHODS AND SYSTEMS FOR DETECTING ALLELIC IMBALANCE IN CELL-FREE NUCLEIC ACID SAMPLES | VASSELL, MEREDITH ABBOTT | 79d overdue |
| 17407000 | METHODS AND SYSTEMS FOR DETERMINING THE CELLULAR ORIGIN OF CELL-FREE DNA | ZEMAN, MARY K | 73d overdue |
| 18907227 | DETECTING THE PRESENCE OF A TUMOR BASED ON METHYLATION STATUS OF CELL-FREE NUCLEIC ACID MOLECULES | SANGHERA, STEVEN G.S. | 67d overdue |
| 19018456 | METHODS FOR EARLY DETECTION OF CANCER | BROWN, MINDY G | 37d overdue |
| 18506858 | METHODS AND COMPOSITIONS FOR COPY-NUMBER INFORMED TISSUE-OF-ORIGIN ANALYSIS | JONES, CHRISTINE MICHELLE | 31d overdue |
| 17823915 | DATA REPOSITORY, SYSTEM, AND METHOD FOR COHORT SELECTION | REYES, REGINALD R | 69d |
| 18920396 | GENOMIC AND METHYLATION BIOMARKERS FOR DETERMINING PATIENT RISK OF HEART DISEASE AND NOVEL GENOMIC AND EPIGENOMIC DRUG TARGETS TO DECREASE RISK OF HEART DISEASE AND/OR IMPROVE PATIENT OUTCOME AFTER MYOCARDIAL INFARCTION OR CARDIAC INJURY | KHATTAR, RAJESH | — |
| 18817550 | METHODS FOR ANALYZING CYTOSINE METHYLATION AND HYDROXYMETHYLATION | GREENE, CAROLYN LEE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18907227 | DETECTING THE PRESENCE OF A TUMOR BASED ON METHYLATION STATUS OF CELL-FREE NUCLEIC ACID MOLECULES | SANGHERA, STEVEN G.S. | 67d overdue |
| 18339116 | METHODS AND SYSTEMS FOR ANALYZING METHYLATED POLYNUCLEOTIDES | WILDER, CYNTHIA B | 60d overdue |
| 19018456 | METHODS FOR EARLY DETECTION OF CANCER | BROWN, MINDY G | 37d overdue |
| 18325759 | COMPOSITIONS AND METHODS FOR ENRICHING METHYLATED POLYNUCLEOTIDES | YU, TIAN NMN | 14d |
| 19239357 | METHODS FOR MULTI-RESOLUTION ANALYSIS OF CELL-FREE NUCLEIC ACIDS | LIU, GUOZHEN | 56d |
| 19637857 | METHODS FOR EARLY DETECTION OF CANCER | WILDER, CYNTHIA B | — |
| 19221319 | METHODS AND SYSTEMS FOR SECURE SOFTWARE DELIVERY | WANG, CHAO | — |
| 18920396 | GENOMIC AND METHYLATION BIOMARKERS FOR DETERMINING PATIENT RISK OF HEART DISEASE AND NOVEL GENOMIC AND EPIGENOMIC DRUG TARGETS TO DECREASE RISK OF HEART DISEASE AND/OR IMPROVE PATIENT OUTCOME AFTER MYOCARDIAL INFARCTION OR CARDIAC INJURY | KHATTAR, RAJESH | — |
| Art Unit | Apps |
|---|---|
| 1681 | 5 |
| 1687 | 5 |
| 1686 | 3 |
| 3684 | 3 |
| 1682 | 3 |
| 2439 | 1 |
| 1683 | 1 |
| 1678 | 1 |
| 3685 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19637857 | METHODS FOR EARLY DETECTION OF CANCER | WILDER, CYNTHIA B | 1681 | §103 | Final Rejection | — | Pending | Apr 02, 2026 |
| 19239357 | METHODS FOR MULTI-RESOLUTION ANALYSIS OF CELL-FREE NUCLEIC ACIDS | LIU, GUOZHEN | 1686 | §103 | Final Rejection | 56d | Pending | Jun 16, 2025 |
| 19221319 | METHODS AND SYSTEMS FOR SECURE SOFTWARE DELIVERY | WANG, CHAO | 2439 | §103 | Non-Final OA | — | Pending | May 28, 2025 |
| 19018456 | METHODS FOR EARLY DETECTION OF CANCER | BROWN, MINDY G | 1683 | §101 | Non-Final OA | 37d overdue | Pending | Jan 13, 2025 |
| 18920396 | GENOMIC AND METHYLATION BIOMARKERS FOR DETERMINING PATIENT RISK OF HEART DISEASE AND NOVEL GENOMIC AND EPIGENOMIC DRUG TARGETS TO DECREASE RISK OF HEART DISEASE AND/OR IMPROVE PATIENT OUTCOME AFTER MYOCARDIAL INFARCTION OR CARDIAC INJURY | KHATTAR, RAJESH | 3684 | §101§103§112 | Final Rejection | — | Pending | Oct 18, 2024 |
| 18907227 | DETECTING THE PRESENCE OF A TUMOR BASED ON METHYLATION STATUS OF CELL-FREE NUCLEIC ACID MOLECULES | SANGHERA, STEVEN G.S. | 3684 | §101§103 | Final Rejection | 67d overdue | Pending | Oct 04, 2024 |
| 18817550 | METHODS FOR ANALYZING CYTOSINE METHYLATION AND HYDROXYMETHYLATION | GREENE, CAROLYN LEE | 1681 | §102§103§112 | Non-Final OA | — | Pending | Aug 28, 2024 |
| 18620056 | METHODS FOR EARLY DETECTION OF CANCER | YU, TIAN NMN | 1681 | §103DP | Non-Final OA | — | Pending | Mar 28, 2024 |
| 18506573 | COMPOSITIONS AND METHODS FOR ASSAYING CIRCULATING MOLECULES | MONTGOMERY, ANN Y | 1678 | §102§103§112 | Non-Final OA | — | Pending | Nov 10, 2023 |
| 18506858 | METHODS AND COMPOSITIONS FOR COPY-NUMBER INFORMED TISSUE-OF-ORIGIN ANALYSIS | JONES, CHRISTINE MICHELLE | 1682 | §102§103§112DP | Final Rejection | 31d overdue | Pending | Nov 10, 2023 |
| 18451739 | DETERMINING A DYNAMIC QUALITY METRIC OF A BIOPSY SAMPLE | LEVERETT, MARY CHANG | 1687 | §101§103§112 | Non-Final OA | — | Pending | Aug 17, 2023 |
| 18339116 | METHODS AND SYSTEMS FOR ANALYZING METHYLATED POLYNUCLEOTIDES | WILDER, CYNTHIA B | 1681 | §103 | Final Rejection | 60d overdue | Pending | Jun 21, 2023 |
| 18325759 | COMPOSITIONS AND METHODS FOR ENRICHING METHYLATED POLYNUCLEOTIDES | YU, TIAN NMN | 1681 | §103DP | Final Rejection | 14d | Pending | May 30, 2023 |
| 18314736 | DETECTING DEGRADATION BASED ON STRAND BIAS | LUO, JAMMY NMN | 1686 | §101§103 | Non-Final OA | — | Pending | May 09, 2023 |
| 18172734 | METHODS AND SYSTEMS FOR PREDICTING AN ORIGIN OF A VARIANT | LI, SUN M | 3685 | §101 | Non-Final OA | — | Pending | Feb 22, 2023 |
| 18050855 | METHODS AND SYSTEMS FOR IMPROVING PATIENT MONITORING AFTER SURGERY | SALMON, KATHERINE D | 1682 | §101§103§112 | Non-Final OA | — | Pending | Oct 28, 2022 |
| 17823915 | DATA REPOSITORY, SYSTEM, AND METHOD FOR COHORT SELECTION | REYES, REGINALD R | 3684 | §101 | Non-Final OA | 69d | Pending | Aug 31, 2022 |
| 17687536 | METHODS AND RELATED ASPECTS FOR ANALYZING MOLECULAR RESPONSE | BUCHANAN, BAILEY CHEYENNE | 1682 | §101§103§112 | Final Rejection | — | Pending | Mar 04, 2022 |
| 17552728 | METHODS TO DETERMINE TUMOR GENE COPY NUMBER BY ANALYSIS OF CELL-FREE DNA | WOITACH, JOSEPH T | 1687 | §101§112Other | Non-Final OA | — | Pending | Dec 16, 2021 |
| 17459743 | COMPUTATIONAL DETECTION OF COPY NUMBER VARIATION AT A LOCUS IN THE ABSENCE OF DIRECT MEASUREMENT OF THE LOCUS | ANDERSON-FEARS, KEENAN NEIL | 1687 | §101§112 | Non-Final OA | — | Pending | Aug 27, 2021 |
| 17407000 | METHODS AND SYSTEMS FOR DETERMINING THE CELLULAR ORIGIN OF CELL-FREE DNA | ZEMAN, MARY K | 1686 | §101 | Final Rejection | 73d overdue | Pending | Aug 19, 2021 |
| 16560752 | METHODS AND SYSTEMS FOR DETECTING ALLELIC IMBALANCE IN CELL-FREE NUCLEIC ACID SAMPLES | VASSELL, MEREDITH ABBOTT | 1687 | §101§112 | Final Rejection | 79d overdue | Pending | Sep 04, 2019 |
| 16429997 | METHODS AND SYSTEMS FOR DETERMINING The CELLULAR ORIGIN OF CELL-FREE NUCLEIC ACIDS | PULLIAM, JOSEPH CONSTANTINE | 1687 | §101§112 | Non-Final OA | — | Pending | Jun 03, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGuardant Health Inc. has 23 pending office actions as of October 2026, spread across 9 art units and 21 examiners.
Cynthia B Wilder has the most, with 2 of Guardant Health Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
